Comparative analysis results of surgical treatment, chemoradiotherapy and chemotherapy with assessment of prognostic factors in cervical esophageal cancer

Cover Page

Cite item

Full Text

Abstract

Aim. To analyze the results of treatment and prognostic factors of survival in patients with cervical esophageal cancer (CEC) who received surgical treatment, chemoradiation therapy and chemotherapy.

Materials and methods. The retrospective study included patients with a verified diagnosis of CEC treated at the Petrov National Medicine Research Center of Oncology from 2009 to 2018 and divided into three treatment groups: surgical treatment, chemoradiotherapy and chemotherapy. The endpoints of the study were overall survival (OS) and relapse-free survival (RFS).

Results. Ninety-seven patients were included in the study: 48 in the surgical group, 30 in the chemoradiotherapy group and 17 patients in the chemotherapeutic treatment group. The average age of patients was 59.2±10.4 years. The median OS in the surgical group was 39.1 months, in the chemoradiotherapy group – 23.9 months and 8.9 months in the chemotherapy group; the overall 3-year survival rate was 51.0% (95% CI 36.4–71.7), 44.9% (95% CI 26.9–74.9) and 26.0% (95% CI 9.9–68.2), respectively. The overall 5-year survival rate for the surgical group and the chemoradiotherapy group was 40.0% (95% CI 25.8–62.0), and 44.9% (95% CI 26.9–74.9), respectively. The presence of coronary heart disease is associated with a significant decrease in OS. The median disease-free survival in the surgical group was 19 months, in the chemoradiotherapy group – 11.5 months and 3.4 months in the chemotherapy group; the relapse-free 3-year survival rates were 44.1% (95% CI 30.2–64.4), 25.0% (95% CI 11.7–53.4) and 14.3% (95% CI 4.0–51.5), respectively. The relapse-free 5-year survival rate for the surgical treatment group and the chemoradiotherapy group was 34.6% (95% CI 21.6–55.3), and 25.0% (95% CI 11.7–53.4). The presence of peptic ulcer disease was statistically significantly associated with higher overall and RFS regardless of the treatment received.

Conclusion. In our study, surgical treatment of the CEC showed better overall and RFS rates compared with chemoradiotherapy. The presence of coronary heart disease and peptic ulcer disease are prognostic factors for overall and RFS.

About the authors

Zamira Ah.-G. Radzhabova

Petrov National Medicine Research Center of Oncology

Author for correspondence.
Email: radzam@mail.ru
ORCID iD: 0000-0002-6895-0497

Cand. Sci. (Med.), Assoc. Prof.

Russian Federation, Saint Petersburg

Maxim A. Kotov

Petrov National Medicine Research Center of Oncology

Email: radzam@mail.ru
ORCID iD: 0000-0002-2586-1240

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Michail M. Girshovich

Petrov National Medicine Research Center of Oncology

Email: radzam@mail.ru
ORCID iD: 0000-0002-7925-9570

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Olga I. Ponomareva

Petrov National Medicine Research Center of Oncology

Email: radzam@mail.ru
ORCID iD: 0000-0002-7004-9630

radiologist

Russian Federation, Saint Petersburg

Elena V. Tkachenko

Petrov National Medicine Research Center of Oncology

Email: radzam@mail.ru
ORCID iD: 0000-0001-6375-8335

Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Alexander S. Mitrofanov

Petrov National Medicine Research Center of Oncology

Email: radzam@mail.ru
ORCID iD: 0000-0001-7490-4019

Graduate Student

Russian Federation, Saint Petersburg

Madina A. Radzhabova

Petrov National Medicine Research Center of Oncology

Email: radzam@mail.ru
ORCID iD: 0000-0001-7679-129X

Clinical Resident

Russian Federation, Saint Petersburg

Evgeniy V. Levchenko

Petrov National Medicine Research Center of Oncology

Email: radzam@mail.ru
ORCID iD: 0000-0003-3837-2515

D. Sci. (Med.), Prof., Corr. Memb. RAS

Russian Federation, Saint Petersburg

References

  1. Hoeben A, Polak J, Van De Voorde L, et al. Cervical esophageal cancer: a gap in cancer knowledge. Ann Oncol. 2016;27(9):1664-74. doi: 10.1093/annonc/mdw183
  2. Ferahkose Z, Bedirli A, Kerem M, et al. Comparison of free jejunal graft with gastric pull-up reconstruction after resection of hypopharyngeal and cervical esophageal carcinoma. Dis Esophagus. 2008;21(4):340-5. doi: 10.1111/j.1442-2050.2007.00781.x
  3. Ma JB, Song YP, Yu JM, et al. Feasibility of Involved-Field Conformal Radiotherapy for Cervical and Upper-Thoracic Esophageal Cancer. Oncologie. 2011;34(11):599-604. doi: 10.1159/000334194
  4. Cao C, Luo J, Gao L, et al. Definitive radiotherapy for cervical esophageal cancer. Head Neck. 2015;37(2):151-5. doi: 10.1002/hed.23572
  5. Gkika E, Gauler T, Eberhardt W, et al. Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Dis Esophagus. 2014;27(7):678-84. doi: 10.1111/dote.12146
  6. Miyata H, Yamasaki M, Takahashi T, et al. Larynx-Preserving Limited Resection and Free Jejunal Graft For Carcinoma of the Cervical Esophagus. World J Surg. 2013;37(3):551-7. doi: 10.1007/s00268-012-1875-7
  7. Chou SH, Li HP, Lee JY, et al. Radical Resection or Chemoradiotherapy for Cervical Esophageal Cancer? World J Surg. 2010;34(8):1832-39. doi: 10.1007/s00268-010-0595-0
  8. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of Locally Advanced Esophageal Cancer: Long-term Follow-up of a Prospective Randomized Trial (RTOG 85-01). JAMA. 1999;281(17)1623-7. doi: 10.1001/jama.281.17.1623
  9. Adelstein DJ, Li Y, Adams GL, et al. An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer. Am Soc Clin Oncol. 2016;21(1):92-8. doi: 10.1200/JCO.2003.01.008
  10. Bonner JA, Ove R, Kies MS, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2009;354(6):567-8. doi: 10.1056/NEJMoa053422
  11. Huang SH, Lockwood G, Brierley J, et al. Effect of Concurrent High-Dose Cisplatin Chemotherapy and Conformal Radiotherapy on Cervical Esophageal Cancer Survival. Int J Radiat Oncol. 2008;71(3):735-40. doi: 10.1016/j.ijrobp.2007.10.022
  12. Stuschke M, Stahl M, Wilke H, et al. Induction Chemotherapy followed by Concurrent Chemotherapy and High-Dose Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Cervical Oesophagus. Oncology. 1999;57(2):99-105. doi: 10.1159/000012015
  13. Mendenhall W, Sombeck MD, Parsons JT, et al. Management of Cervical Esophageal Carcinoma. Semin Radiat Oncol. 1994;4(3):179-91. doi: 10.1053/SRAO00400179
  14. Tong DK, Law S, Kwong DL, et al. Current Management of Cervical Esophageal Cancer. World J Surg. 2011;35(3):600-7. doi: 10.1007/s00268-010-0876-7
  15. Kadota H, Sakuraba M, Kimata Y, et al. Larynx-preserving esophagectomy and jejunal transfer for cervical esophageal carcinoma. Laryngoscope. 2009;119(7):1274-80. doi: 10.1002/lary.20493
  16. Ott K, Lordick F, Molls M, et al. Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg. 2009;96(3):258-66. doi: 10.1002/bjs.6437
  17. Triboulet JP, Mariette C, Chevalier D, Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus: Analysis of 209 cases. Arch Surg. 2001;136(10):1164-70. doi: 10.1001/archsurg.136.10.1164
  18. Cao CN, Luo JW, Gao L, et al. Primary Radiotherapy Compared With Primary Surgery in Cervical Esophageal Cancer. JAMA Otolaryngol Neck Surg. 2014;140(10):918-26. doi: 10.1001/jamaoto.2014.2013
  19. Dudhat SB, Mistry RC, Fakih AR. Complications following gastric transposition after total laryngo-pharyngectomy. Eur J Surg Oncol. 1999;25(1):82-5. doi: 10.1053/ejso.1998.0605

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig 1. Overall survival in patient groups.

Download (77KB)
3. Fig 2. Relapse-free survival rate in patient groups.

Download (79KB)

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).